BMS-P5

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

BMS-P5 是一种具有口服活性的特异性肽基精氨酸脱亚胺酶 4 (PAD4) 抑制剂。

BMS-P5 is a specific and orally active Peptidylarginine Deiminase 4 (PAD4) inhibitor.

BMS-P5 blocks calcium ionophore-induced citrullination of histone H3.BMS-P5 is also able to inhibit formation of NETs induced by primary MM cells isolated from the BM of patients with MM. Cell Viability Assay Cell Line:Neutrophils.Concentration:10 μM and 100 μM.Incubation Time:30 min followed by addition of DP42 or 5TGM1 CM.Result:Prevented MM-induced NET formation.

BMS-P5 (50 mg/kg, oral gavage) significantly improves survival of MM-bearing mice.BMS-P5 (50 mg/kg, oral gavage) may attenuate the presence of pro-tumorigenic proteins in the tumor microenvironment, and thus delay tumor progression. Animal Model:Syngeneic mouse model of MM.Dosage:50 mg/kg.Administration:Oral gavage, twice a day beginning on day 3 after tumor cell injection.Result:Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice.

——

Others

Other Targets

COX|HO-1|NOS|Nrf2|PKC

——

——

1549811-36-0

509.04

C27H33ClN6O2

>98% (HPLC)

——

O=C(C1=CC(OC)=C2C(N=C(N2C)C3=CC4=CC=CN=C4N3CC5CC5)=C1)N6[C@H](CC[C@H](C6)N)C.Cl

——

(-20℃)

With Ice Pack

≥ 2 years